Search Search
User Profile
Change
Select your user profile

Point of Care clinical chemistry and immunoassay solutions

Clinical chemistry and immunoassay Point of Care solutions for various healthcare settings.

Find your product Contact us
A gray-haired man and a woman hugging each other and smiling

Actionable insights right at your fingertips—to make a difference in cardiometabolic testing when time matters most

Cardiometabolic diseases pose a major health threat, with risk factors such as obesity, diabetes, and unhealthy habits driving a rise in heart disease, stroke, and other serious illnesses. Aging demographics are contributing to the rise of these diseases.1 Access to cardiometabolic diagnostic tests is vital, as early detection and intervention are key to preventing complications and the progression of the disease.2

Our comprehensive suite of trusted and innovative Point of Care (POC) clinical chemistry and immunoassay solutions empowers you to early detect, treat, and monitor major cardiometabolic diseases across various settings.

From ambulances, clinics, outpatient wards, and pharmacies to emergency rooms—we offer solutions to meet your every need.

Discover lab-like accuracy in versatile, portable devices designed for intuitive use, alongside robust and reliable benchtop analyzers. Combined with our POC digital solutions, our clinical chemistry and immunoassay POC portfolio not only delivers fast results every time they matter, but also simplifies clinical workflows and device management. Enhance your clinical decision-making with actionable insights to improve medical outcomes and make a difference in the overall patient experience.

Featured products

Find your product

Benefits of clinical chemistry and immunoassay solutions

Make a difference when and where fast and reliable results matter most

  • Ensure timely intervention: POC Troponin T testing helps to quickly identify patients at high risk of acute myocardial infarction in the pre-hospital settings, allowing for immediate triage and the appropriate treatment.3-6
  • Support preventative care strategies: POC NT-proBNP testing provides objective results to help identify type 2 diabetes patients at risk for cardiovascular complications, allowing for more targeted care and improved outcomes.7
  • Help improve outcomes with disease monitoring: For individuals with diabetes, POC HbA1c testing helps increase the number of diabetes patients achieving optimal glycaemic control.8
  • Enable better patient experiences and outcomes: Regular monitoring of patients with chronic diseases during the consultation can equip physicians to educate and motivate patients. Test results and treatment options can be discussed with the patient during the same consultation, helping to reduce anxiety, waiting time, and additional appointments.9

Advanced diagnosis and monitoring for early detection and effective management of cardiometabolic diseases

  • Offer accurate and reliable results: All clinical chemistry and immunoassay testing results of Roche POC analyzers are validated against Roche reference methods for comparable results and seamless integration with laboratory testing.10-13
  • Enable efficient lab control: navify® POC digital solutions enable efficient lab control by providing a comprehensive view of Point of Care operations, facilitating improved device management, data analysis, and personalized insights. It also helps ensure compliance by automating processes related to training, certification, and documentation for accreditation, staying ahead of regulatory requirements.

Easy to use and maintain devices and digital solutions for decentralized care settings

  • Experience user-friendly design: Easy-to-use Point of Care analyzers with fingerprick sampling and test storage at room temperature contribute to simplify workflows and device management in decentralized settings.14
  • Implement operational efficiency: navify® POC digital solutions securely integrate data wherever care gets delivered, enhancing clinical workflows to alleviate staff shortages and simplifying device management.
  • Help improve patient flow: Immediate results at the point of need help to improve efficiency and initiate treatment faster, reduce patient follow-up visits, reduce patient waiting times and provide the appropriate care pathway to patients sooner.15,16

Cost-effective solutions that boost the patient's experience

  • Promote earlier diagnosis: POC NT-proBNP testing results in earlier diagnosis and lower costs than laboratory testing or clinical diagnosis alone.17
  • Support economic sustainability: Studies show switching from lab testing to POC HbA1c for monitoring type 2 diabetes in primary care is cost-effective—a Canadian analysis estimated annual savings of CAD $4.7 million across the healthcare system.18
  • Enable reduced inappropriate antibiotic use: POC CRP testing has been shown to be a cost-effective way to reduce inappropriate antibiotic use in primary care.19,20
  • Help achieve reduced hospitalization and medical visits: Studies have shown that the use of NT-proBNP for chronic heart failure diagnosis in primary care can reduce hospitalizations by 14.4%. The reduction in medical visits was higher in the POC setting - 38% compared to 2.5% in the lab settings- resulting in higher savings.21
What our customers say
icon of a blue speech bubble on grey background

Pre-hospital measuring of blood samples are routinely used in the Central Denmark Region to identify patients with minor myocardial infarctions. This technology is required to identify patients in the ambulance and refer them directly to the heart center for accelerated coronary artery examination and possible balloon dilation. The benefit is an earlier diagnosis, treatment, and discharge.

Christian Juhl Terkelsen
MD, DmSc, PhD, Professor, FESC

Critical seconds: The life-saving impact of Roche Troponin T testing

Watch Now: Discover how Roche Troponin T testing enabled early intervention after a cardiac event. This film highlights the critical role of near-patient testing solutions in dramatically improving outcomes when time is of the essence.

Critical seconds: The life-saving impact of Roche Troponin T testing
Erna Lenters-Westra

HbA1c Point of Care testing: is it good enough for clinical practice? - Erna Lenters-Westra

Value in clinical practice: HbA1c Point of Care Testing (POCT) for better diabetes care.

Dr. Jacob Thorsted Sørensen

Point of Care Troponin as a decision aid in the prehospital setting - Jacob Thorsted Sørensen

Is Point of Care Troponin key to unlocking more efficient care for Acute Coronary Syndrome?

Management of chronic heart failure with Point of Care NT-proBNP

Watch the story of Paul and the management of his chronic heart failure with Point of Care NT-proBNP.

Management of chronic heart failure with Point of Care NT-proBNP

You might be interested in

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Form Successfully Submitted!
Thank you for your submission!
text
close
Contact us

Related health topics

Images on this page are used for illustrative purposes only; any person depicted in the content is a model.

References

  1. Rodgers J et al. Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019;6(2):19.
  2. Cheng X et al. Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States. Int J Environ Res Public Health. 2022;19(8):4726.
  3. Roche CARDIAC POC Troponin T Method Sheet Version 3.0.
  4. Rasmussen MB et al. Predictive value of routine point-of-care cardiac troponin T measurement for prehospital diagnosis and risk-stratification in patients with suspected acute myocardial infarction. Eur Heart J. 2017;1–10.
  5. Stengaard C et al. Quantitative point-of-care troponin T measurement for diagnosis and prognosis in patients with a suspected acute myocardial infarction. Am J Cardiol. 2013;112: 1361-1366.
  6. Martin-Rodriguez F et al.  Prehospital troponin as a predictor of early clinical deterioration. Eur J Clin Invest. 2021; 51: e13591.
  7. Huelsmann M et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365-1372.
  8. Motta LA et al. Point-of-care testing improves diabetes management in a primary care clinic in South Africa. Prim Care Diabetes. 2017;11(3):248-253.
  9. Mueller C et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. ESC Practical Guidance. Eur Heart J. 2019;21: 715-73.
  10. Roche CARDIAC POC NT-proBNP Method Sheet Version 1.0.
  11. Roche Diagnostics International Ltd. cobas® HbA1c Test Method Sheet Version 2.0.
  12. Coqueiro RS et al.Validity of a Portable Glucose, Total Cholesterol, and Triglycerides Multi-Analyzer in Adults. Biol Res Nurs. 2014;16(3):288-294.
  13. Roche (2023). Measured method comparison of cobas® c 503 vs. cobas® c 111. Data on file.
  14. Roche Diagnostics International Ltd. cobas® b 101 system Operator’s Manual Version 2.1.
  15. Schnell O et al. Impact of HbA1c testing at point of care on diabetes management. J Diabetes Sci Technol. 2017;11:611–617.
  16. Patzer KH et al. Implementation of HbA1c point of care testing in 3 German medical practices: Impact on workflow and physician, staff, and patient satisfaction. J Diabetes Sci Technol. 2018;12:687-694.
  17. Bugge C et al. Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study. BJGP Open. 2018;2(3).
  18. Chadee A et al. Point-of-care hemoglobin A1c testing: A budget impact analysis. Ont Health Technol Assess Ser. 2014;14(9):1–23.
  19. Cals JWL et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract. 2011;17(6):1059-1069.
  20. Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England . Adv Ther. 2015; 32(1):69-85.
  21. Fonseca C et al. NT-proBNP for heart failure diagnosis in Primary Care: Costs or savings? A budget impact study. Rev Port Cardiol. 2022; 41(3):183-193.